DOVE | APGOT-OV7/ENGOT-ov80

The DOVE trial is a Phase II, randomised study evaluating the efficacy and safety of dostarlimab alone or with bevacizumab versus nonplatinum chemotherapy in recurrent gynaecological clear cell carcinoma.

DOVE | APGOT-OV7/ENGOT-ov802025-09-11T16:18:58+10:00

RAMP-301 | NCT06072781

The RAMP-301 trial will assess the safety and efficacy of the combination of Avutometinib plus Defactinib versus Investigator’s Choice of Treatment options (ICT) in patients with recurrent Low-grade Serous Ovarian Cancer (LGSOC) who have progressed on a prior platinum-based [...]

RAMP-301 | NCT060727812024-07-19T11:32:01+10:00

EN.10/TAPER | NCT05640999

The primary objective of this study is to estimate the rate of pelvic recurrence at 3 years in patients who are treated with de-escalated adjuvant treatment directed by tumour molecular status.

EN.10/TAPER | NCT056409992024-07-09T16:59:38+10:00
Go to Top